BeyondSpring Doses First Patient With Pembrolizumab, Plinabulin Plus Etoposide/Platinum In A Phase 2 Investigator-Initiated Study Of First-Line Extensive-Stage Small-Cell Lung Cancer

Current treatment for first-line ES-SCLC includes EP and EP plus PD-L1 antibodies. Although the objective response rate (ORR) is high (around 60-65%), median progression free survival (PFS) remains low (< 6 months), with median overall survival at 10-13 months1,2. Therefore, 1L ES-SCLC remains a serious unmet medical need.